Bioton S.A. | Income Statement

Fiscal year is January-December. All values PLN Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
340,358.00
377,303.00
404,408.00
277,613.00
361,649.00
241,166
Cost of Goods Sold (COGS) incl. D&A
194,551.00
213,526.00
230,363.00
141,331.00
175,534.00
122,867
Gross Income
145,807.00
163,777.00
174,045.00
136,282.00
186,115.00
118,299
SG&A Expense
128,143.00
142,465.00
156,720.00
147,581.00
161,133.00
164,216
EBIT
8,621.00
22,703.00
19,025.00
11,231.00
19,433.00
51,111
Unusual Expense
118.00
721.00
554,113.00
-
-
1,072
Non Operating Income/Expense
7,211.00
17,837.00
191.00
1,214.00
13,710.00
67,141
Interest Expense
16,036.00
19,225.00
14,067.00
10,920.00
11,776.00
8,029
Pretax Income
2,301.00
23,431.00
547,051.00
20,798.00
5,841.00
15,168
Income Tax
8,670.00
10,433.00
26,418.00
4,810.00
8,624.00
10,920
Consolidated Net Income
6,369.00
12,998.00
520,633.00
15,988.00
14,465.00
26,088
Net Income
6,443.00
13,428.00
522,855.00
16,116.00
14,537.00
26,266
Net Income After Extraordinaries
6,443.00
23,178.00
522,855.00
3,665.00
21,808.00
26,266
Net Income Available to Common
6,443.00
7,724.00
522,855.00
28,567.00
7,266.00
26,266
EPS (Basic)
0.08
0.04
6.09
0.33
0.08
0.31
Basic Shares Outstanding
84,529.70
85,864.20
85,864.20
85,864.20
85,864.20
85,864.20
EPS (Diluted)
0.08
0.04
6.09
0.33
0.08
0.31
Diluted Shares Outstanding
84,529.70
85,864.20
85,864.20
85,864.20
85,864.20
85,864.20
EBITDA
38,602.00
56,443.00
56,306.00
20,062.00
51,549.00
21,618
Other Operating Expense
9,043.00
1,391.00
1,700.00
68.00
5,549.00
5,194
Non-Operating Interest Income
2,387.00
1,395.00
2,295.00
139.00
212.00
5,337
Minority Interest Expense
74.00
430.00
2,222.00
128.00
72.00
178

About Bioton

View Profile
Address
Macierzysz, ul. Poznanska 12
Warsaw MZ 05
Poland
Employees -
Website http://www.bioton.pl
Updated 07/08/2019
BIOTON SA engages in the manufacture and production of medicines and pharmaceutical substances. The company offers oral hypoglycemic drug, foot cream and human insulin. It operates through the following segment: BIOTON S.